What is NDC 62135-947?

62135-947 is the product NDC for Repaglinide, Repaglinide 1 mg/1 tablet, listed with the FDA by Chartwell RX, LLC. It has 1 package NDC, shown above in 10- and 11-digit form.

Chartwell RX, LLC, NDC labeler code 62135. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Repaglinide?

17 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Repaglinide NDC 62135-947 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)62135-947Labeler and product segments. Claims need a package NDC.

Product NDC at billing width62135-0947Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
62135-947-90	6213509479062135094790	90 TABLET in 1 BOTTLE (62135-947-90)Marketed from Apr 24, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Repaglinide
Generic name (nonproprietary): repaglinide
Active ingredients: Repaglinide — 1 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Chartwell RX, LLCNDC labeler code 62135
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 078555
Marketing start: Jan 22, 2014
Listing expires: Dec 31, 2026
Other FDA classes: Potassium Channel Antagonists (Mechanism)
Identifiers: Product ID 62135-947_342983dc-ded9-2234-e063-6294a90ac97fSPL ID 342983dc-ded9-2234-e063-6294a90ac97fSPL set ID cb995e92-295e-4638-a064-978211f5afe1RxCUI 200256, 200257, 200258UNII 668Z8C33LUUPC 0362135948900, 0362135947903, 0362135946906
Pharmacologic class: Glinide

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N462135094790 followed by a unit qualifier and the quantity

Package 62135-0947-90. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 2, 2025.

Indications (excerpt from the label)

Repaglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitation of Use: Repaglinide tablets should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. Repaglinide is a glinide indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus ( 1 ). Limitation of Use: Not for treatment of type 1 diabetes mellitus or diabetic ketoacidosis ( 1 ).

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 62135-947

What is NDC 62135-947?: 62135-947 is the product NDC for Repaglinide, Repaglinide 1 mg/1 tablet, listed with the FDA by Chartwell RX, LLC. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Repaglinide.
What is the active ingredient?: Repaglinide.
Who is the labeler?: Chartwell RX, LLC, NDC labeler code 62135. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Repaglinide?: 17 other product NDCs are listed under this name. See all Repaglinide NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Repaglinide NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Repaglinide	Repaglinide .5 mg/1	TabletOral	NorthStar RxLLC	72603-810	72603-0810-01
Repaglinide	Repaglinide 1 mg/1	TabletOral	NorthStar RxLLC	72603-811	72603-0811-01
Repaglinide	Repaglinide 2 mg/1	TabletOral	NorthStar RxLLC	72603-812	72603-0812-01
Repaglinide	Repaglinide .5 mg/1	TabletOral	Macleods Pharmaceuticals Limited	33342-248	33342-0248-1133342-0248-44
Repaglinide	Repaglinide 1 mg/1	TabletOral	Macleods Pharmaceuticals Limited	33342-249	33342-0249-1133342-0249-44
Repaglinide	Repaglinide 2 mg/1	TabletOral	Macleods Pharmaceuticals Limited	33342-250	33342-0250-1133342-0250-44
Repaglinide	Repaglinide .5 mg/1	TabletOral	Bryant Ranch Prepack	71335-2554	71335-2554-0171335-2554-02
Repaglinide	Repaglinide 2 mg/1	TabletOral	Bryant Ranch Prepack	71335-2598	71335-2598-01
Repaglinide	Repaglinide 1 mg/1	TabletOral	American Health Packaging	60687-560	60687-0560-21
Repaglinide	Repaglinide .5 mg/1	TabletOral	Rising Pharma Holdings, Inc.	57237-157	57237-0157-0157237-0157-05

All 18 Repaglinide NDCs

Other NDCs under ANDA 078555

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 078555
Product	Strength	Form · route	Labeler	Product NDC
Repaglinide	Repaglinide .5 mg/1	TabletOral	Chartwell RX, LLC	62135-946
Repaglinide	Repaglinide 2 mg/1	TabletOral	Chartwell RX, LLC	62135-948